Terms such as 'potentiation', 'synergistic action', 'adverse effects or side effects' or 'idiopathic and idiosyncratic effects', are encountered very frequently in the field of pharmacology. It has widely been recognized that many drugs exhibit complex pharmacologies[@b1][@b2]. However complete molecular bases for many of these are not as yet delineated. Complexity in drug action is best explained by appreciating that drug molecules often interact with multiple proteins[@b3][@b4]. While many unintended interactions lead to adverse pharmacological effects and are hence undesirable[@b5], some others exhibit beneficial and synergistic effects and are therefore highly desirable[@b6]. While it is common knowledge that drugs cause adverse effects or side effects, beneficial effects due to plurality of interactions by drug molecules with selected targets are only now beginning to be appreciated. As a result, the term 'polypharmacology' has been coined[@b3] which aims to achieve the desired therapeutic effect through modulation of more than one target typically by a single drug, in contrast to the term 'polypharmacy' which refers to achieving the therapeutic effect through a combination of drugs acting on different targets. A systems perspective is essential to understand polypharmacology, since it is essentially an emergent property of the system as a whole[@b7]. Examples of drugs affecting multiple targets include clozapine; a drug used to treat schizophrenia, also known to interact with both dopaminergic and serotonergic receptors[@b8]; methadone, a known μ-opioid receptor agonist that also inhibits NMDA leading to more effective action against neuropathic pain[@b9]. Similarly, imatinib (Gleevec), a widely used anticancer drug designed to inhibit BCR-Abl1, a defective tyrosine-kinase protein expressed in chronic myelogenous leukemia (CML) condition due to abnormal chromosomal rearrangement, is also known to affect receptor tyrosine kinases (RTK), that include platelet derived growth factor receptor (PDGFR) and c-kit transmembrane kinase, perhaps contributing to its efficacy[@b10]. A similar effect is observed in case of valproic acid, an approved drug to treat bipolar disorders by possibly acting on voltage-dependent sodium channels. It is additionally known to inhibit histone deacetylases, gamma-amino butyric acid receptors, possibly also cyclooxygenase and effective for treatment of tumors and Alzheimer\'s disease as well[@b11][@b12].

It is clear from these examples that targeting multiple targets simultaneously holds promise for achieving higher therapeutic efficacy than with one best target at a time for treatment of multi- factorial diseases. The problem then can be translated to selecting multiple targets that are amenable for manipulation with a single drug and then rationally design polypharmacological drugs. Identification of such target sets poses several challenges. An approach capturing both global perspectives using systems biology methods and simultaneously atomic level detail of individual molecules in the proteome using structural analyses is necessary to first understand the basis for polypharmacology and then to predict or even design such behavior in new drugs. As a case study, for *M. tuberculosis*, the causative organism of tuberculosis, we illustrate how concepts of polypharmacology can be understood and applied in a systematic manner by adopting a structural proteomics approach that analyses binding sites at a genome scale and identifies promising drug candidates from approved and potential drug databases.

Tuberculosis (TB) causes around 8.6 million new infections and 1.3 million deaths every year and has been one of the largest killers among infectious diseases for several decades now, despite the availability of a handful of chemotherapeutic agents, the BCG vaccine and an extensive effort by the medical community to tackle the disease[@b13]. The situation warrants discovery of newer drugs to combat the causative pathogen *Mycobacterium tuberculosis* (Mtb). Important problems confronting treatment of tuberculosis are prolonged therapy, emergence of drug resistance, and co-morbidity with immunosuppressive diseases, such as HIV. This is in addition to the problem of the latency, which refers to the ability of the pathogen to enter and reside in a dormant state, inaccessible to conventional therapy that can reactivate to an infectious state, even after several decades. A survey of the mechanism of action of clinically used drugs currently indicates that these drugs act through only a handful of target proteins, covering only a small percentage of biological processes in the microbe. Several studies have indicated that there are many more proteins and processes that could be potentially targeted, but are yet to be exploited systematically[@b14][@b15][@b16][@b17][@b18][@b19][@b20].

The objective of this study is to detect and characterize the pocketome[@b21] of *Mtb* with a structural perspective so as to identify strategic target sets for polypharmacology. The pocketome here refers to the sum total of all the putative binding sites within the proteome and a 'target set' refers to the groups of targets sharing similarity in their ligand binding pockets. To address these aspects, two critical inputs are required. First, structural models at a proteome scale and second, powerful and efficient computational tools to mine such proteome scale structural data are both required. Recently, we have built structural models covering 70% of the *Mtb* proteome, which we utilize for this study. We also take advantage of the suite of computational algorithms that have been recently developed in our laboratory for binding site detection[@b22], comparison[@b23][@b24] and functional characterization[@b25]. Using automated methods for comparing binding pockets[@b23][@b24], a first level function annotation was obtained in that study[@b26]. Here, we report (a) characterizing the pocketome to obtain proteome-wide ligand associations, (b) identifying number of pocket types present in *Mtb* proteome, (c) identifying clusters of similar pockets in the proteome, (d) estimating druggability among such pocket clusters and (e) identifying target sets with a polypharmacological potential. We also take advantage of an earlier study in the laboratory that identified potential drug targets using a multilevel pipeline[@b19] integrating systems level interactome analysis, sequence and structural uniqueness as compared to the host genome along with experimentally derived gene essentiality data[@b27][@b28]. The 451 targets identified through these multiple filters are now assessed for their polypharmacological potential and for estimating druggability with a new perspective. We thus, develop a novel approach to identify target sets suitable for polypharmacological intervention and demonstrate that rational selection of polypharmacological targets is theoretically possible, which holds promise for rational design of polypharmacological drugs. The approach is generic and has the potential to be applied widely in drug discovery.

Methods
=======

Proteome-scale structural models and pocketome detection
--------------------------------------------------------

Structural models of the Mtb proteome were obtained from a recent study by our group[@b26]. Crystal structures of 324 Mtb proteins available in PDB and 2737 comparative models that we generated in that study together account for about 70% of the proteome. Since the reliability of the protein structural models is central to all the analysis being performed in this study, utmost care was taken to choose only reliable protein structure models. Methods for structure verification included statistical scoring potential[@b29][@b30], secondary structure compatibility[@b31] and stereochemical quality check[@b32]. Multi-domain protein structures were also included wherein the models of various regions of proteins are present. However only those binding sites that were largely contained within the domains are analyzed here, which leaves out those sites that may be present at the interfaces. This holds for oligomeric proteins as well where each subunit is modeled separately and a template for the whole complex is unavailable. More information on these structures can be found at <http://proline.biochem.iisc.ernet.in/mtbpocketome/materials.php>.

Identification of binding sites
-------------------------------

Different algorithms are available for detection of binding sites in protein structures. Consensus identification from different methods was used to detect the high-confidence pockets from the proteome. The individual methods used for this are PocketDepth (PD)[@b22], a grid-based geometric method, Ligsite[@b33], that captures evolutionary information and SiteHound[@b34], an energy based method. PD, an in-house method that uses a depth-based clustering algorithm for detecting putative binding sites in the given protein structures, where a notion of centrality of empty subspaces in the protein defines depth, was initially used to obtain pockets. This algorithm was combined with LIGSITEcsc[@b33], which captures surface-solvent-surface events involving grooves using Connolly\'s surface[@b35] and maps the degree of conservation of the residues in the selected surface to detect binding sites in a given protein. In addition to the pockets identified by these methods, binding sites were also selected based on the experimental information available directly for that protein or inferred from its homologues. For this, database entries were mined using the respective general feature format files (GFF) obtained from Uniprot database[@b36] (workflow in [Figure S1](#s1){ref-type="supplementary-material"}). Finally, known binding motifs documented in Prosite[@b37] were scanned against each protein sequence in the proteome to identify possible binding sites.

Genome-wide binding site comparisons
------------------------------------

The binding sites obtained were compared using an in-house algorithm -- PocketMatch (PM)[@b23]. PM computes shape descriptors of the pockets and compares sorted arrays of all-pair distance elements grouped into 90 combinations of chemical type pairs to calculate a combined similarity score between pairs of binding sites. All--pair combinations of 13858 binding sites that involved over 192 million comparisons could be accomplished using PM on a Intel(R) Core(TM) x86_64 i7-2600 CPU @ 3.40 GHz with Linux Mint 14 platform. Two types of scores are reported from pair-wise comparison of binding sites -- PMIN, that captures local similarities and the PMAX score that captures global similarities of the pocket as a whole, along with a measure of statistical significance for each score. From our previous studies we know that PMAX score of ≥0.4 reflects meaningful similarities in binding sites, while PMAX ≥ 0.6 denotes meaningful and significant levels of similarities[@b25]. A default cut-off of PMAX ≥ 0.6 is used in this study. However, depending upon the question addressed, and the level of stringency required at a particular step the threshold has been varied for specific analyses, and explicitly stated in the relevant sections ([Table S1](#s1){ref-type="supplementary-material"}). A statistical significance is also computed for each comparison as described by us previously[@b25]. A p-value threshold of 1E-04 has been adopted to identify statistically significant similarities.

Binding site similarity network construction and clustering
-----------------------------------------------------------

To represent similarities in the pocketome, a network formulation was used. Each binding site in the pocketome is represented as a node whereas similarities between pairs of sites are represented as edges (Network-type 1, [Table S2](#s1){ref-type="supplementary-material"}). Clustering is performed on this network to group similar binding sites. MCODE algorithm[@b38], is a well-known automated method to detect highly interconnected subgraphs/clusters within a given network (node score cutoff = 0.2, K-core value = 2 and max depth = 100) through a Cytoscape[@b39] plugin. Each cluster obtained from this analysis is referred to as sets. Although there exist many tools for obtaining the highly connected subcomponents from the network[@b40][@b41], many of these including MCODE face the problem of resolution level of clusters[@b42]. This problem can be alleviated to some extent in this case of binding site similarity network by increasing the cut-off, which has been set to PMAX ≥ 0.7. Invariably exact number of clusters obtained is dependent on the thresholds used irrespective of the clustering method. With a threshold set at such high level, the clusters identified are of high confidence although it comes at the cost of losing some information on site similarity below the threshold. In addition we establish the biological significance of the threshold used by carrying out the same analysis on the PDB pockets derived from MOAD database which resulted in obtaining meaningful clusters with highly similar ligands as judged by average Tanimoto chemical similarity \~ 0.8, and hence we proceeded with the workflow. Other network properties such as disconnected components, degree distribution, clustering coefficient, betweenness and Eigen centrality are calculated using the igraph package[@b43]. To answer the precise question being addressed, a suitable network formulation is used. Description of the network variants constructed in this study along with the specific purpose is given in [Table S2](#s1){ref-type="supplementary-material"}.

Sequence-structure-pocket comparisons
-------------------------------------

Pairwise structure comparison was carried out using TM-Align software[@b44]. TM-Align compares a given pair of folds and reports an optimal alignment. Sequence similarity for each pair was then computed from the corresponding sequences using BLAST2[@b45], a widely used tool for alignment of sequences. Sequence and structure similarity scores were calculated only for pairs of proteins with significant pocket similarities (PMAX of ≥0.60). The pocket-similarity score; sequence-similarity score and structure-similarity score (TM Score) were then used as axes to plot a 3D scatterplot. A TM-score of ≥0.4 is known to indicate significant simlarity[@b44] and is the suggested cut-off for this algorithm. The data points were manually binned into three-different categories: (a) low structural and low sequence similarity (TMScore \< 0.4 and sequence identity \< 30%), (b) high structural but low sequence similarity (TMScore \> 0.4 and sequence identity \< 30%) and (c) high structural and high sequence similarity (TMScore \> 0.4 and sequence identity \> 30%).

Drug binding sites
------------------

A combined list of drugs or drug-like compounds was prepared from DrugBank[@b46] and DrugPort (<http://www.ebi.ac.uk/thornton-srv/databases/drugport/>). These included approved drugs, experimental drugs and nutraceuticals. The binding sites were then extracted from these complexes by considering complete residues of all atoms that lie within 4.5Å of any atom from the drug molecule. 10658 drug-binding sites reported in Drugbank and 2516 reported in Drugport were obtained from PDB through this process (full list is provided at <http://proline.biochem.iisc.ernet.in/mtbpocketome/methods.php>) and is referred to as 'knowndrug-sites_DB' here after. These known drug-binding sites were then scanned for similarities against different binding site clusters and also against high-confidence targets from *Mtb*. A subset of 'approved drug-sites' containing 399 compounds and 3112 binding sites is also derived from 'knowndrug-sites_DB'.

Polypharmacological index (PPI)
-------------------------------

A polypharmacology druggability score referred to as PPI was computed for each binding site by considering three aspects: (a) to score positively the similarity of the sites to other sites in the pocketome and thus contribute to polypharmacological profile of the target, (b) to score positively for those sets of sites that resemble any 'approved drug-sites' and thus captures druggability and (c) to penalize those sites that exhibit similarity to cofactor binding sites since that would increase chances of adverse polypharmacology[@b7][@b47], thus capturing specificity. The first and second aspects refer to desired attributes and hence get a positive score, while the third aspect is penalized so as to improve specificity. For this, a separate dataset of 29215 cofactor-binding sites was created from PDB (<http://proline.biochem.iisc.ernet.in/mtbpocketome/methods.php>). The list of cofactors were manually extracted from PDB and mined from the Cofactor Database[@b48]. Each pocket was compared to these cofactor-binding sites using PM. Each pocket was then scanned against 'approved-drug binding sites' described earlier. A scoring scheme was generated to rank the pockets for their druggability such that the score: In [equation (1)](#m1){ref-type="disp-formula"}, DH = No. of drug binding site hits ≥ PMAX 0.5, DDB = Size of drug binding site database (\~3112), CH = No. of cofactor binding sites hits ≥ PMAX 0.6 and P-value \~ 1E-04, CDB = Size of cofactor binding sites database and CC~PMAX≥0.6~ is clustering coefficient of binding site derived from binding site similarity network at PMAX ≥ 0.60.

Validation
----------

A validation component was included for each of the aspects involved in this study. Different prediction steps that have been validated are as follows: (i) pocket detection using the consensus approach, (ii) ligand associations through PM scores, (iii) clustering of similar sites from networks, and (iv) inferring drug binding from pocket level similarities. Both PD and PM algorithm have already been extensively validated through use of appropriate datasets (PD[@b22] and PM[@b23]). Further, in this study a large-scale comparison with the crystallographically derived sites from the Procognate database[@b49] has been carried out. In 2442 of 3209 complexes, a pocket at a similar location as well as the same ligand association is predicted. The entire site-based function annotation pipeline has also been validated in PocketAnnotate[@b25] using apo-holo protein datasets. Put together, it is clear that methods used for binding site identification, measuring similarities between binding sites and obtaining ligand associations based on binding site similarities are sufficiently reliable.

To validate the method of clustering, a binding-site similarity network of protein-ligand complexes from PDB was constructed (Network-type 2, [Table S2](#s1){ref-type="supplementary-material"}). The protein-ligand complexes were obtained from BindingMOAD database[@b50] that stores the information of binding sites in the PDB. Around 16275 binding sites were derived from the database and all-versus-all (that amounts to \~132 million) comparisons were carried out using PM. A binding-site similarity network was constructed with similar cut-offs as used for Mtb pocketome (Network-type 1, [Table S2](#s1){ref-type="supplementary-material"}) and identical protocol was followed for clustering. Around 1777 clusters were found and majority of the clusters contained binding sites specific for similar ligands as judged from their Tanimoto scores calculated from open Babel toolbox[@b51]. As many as 1410 of these clusters show an average Tanimoto score of more \>0.8 for the chemical fingerprints of the ligands associated with them, reflecting that not only are the sites similar to each other within each cluster, but the ligands they bind to are also very similar. This validates the clustering algorithm as the binding sites that interact with chemically similar ligands are grouped into the same cluster.

Finally, for the predicted associations, a validation exercise was carried out to test the geometric compatibility and energetic feasibility of binding of that drug to the corresponding pocket. To do this, the predicted drug was docked onto its corresponding target using Autodock Vina[@b52] and the intermolecular binding energy computed. Since drug associations are predicted from binding sites derived from experimentally resolved protein-drug complexes, intermolecular energies between the drug and the corresponding protein in PDB from which the binding site was derived could also be easily calculated. The intermolecular energies from the docked complexes were then systematically compared with the corresponding experimental complexes and a ratio of the two was computed in each case. 1337 docking exercises were performed and of these, in around 87% of the cases, the interaction scores obtained were similar (ratio of scores \> 0.7) to that of native drug complexes. This serves to independently verify our drug association method based on binding site similarities, as it estimates the feasibility of predicted interactions in the *Mtb* pockets.

Complete datasets along with supporting files for this section is made available at <http://proline.biochem.iisc.ernet.in/mtbpocketome/methods.php>. A detailed list of all the tools and the databases used in the workflow is also listed in [supplementary (Table S3)](#s1){ref-type="supplementary-material"}.

Results
=======

This study has resulted in obtaining a global perspective of small molecule binding sites in the proteome of *Mtb*. Most notably, through a single study of the pocketome, hundreds of binding sites are analyzed in detail, obtaining possible drug associations for the entire set of promising targets in *Mtb*, as described in the following sections. To the best of our knowledge, this is the first study that comprehensively characterizes the pocketome and the binding site similarities within it, at a genome scale for any organism.

Mapping the small molecule binding pocket space in *Mtb*: characterization of the *Mtb* pocketome
-------------------------------------------------------------------------------------------------

Availability of protein structures at a proteome scale and well-validated methods to identify small molecule ligand binding pockets renders it feasible to map the binding pocket space in the organism. Understanding the pocketome of *Mtb* provides ready answers to several questions such as (a) how many pocket or site-types are present in *Mtb*, (b) what are the small molecule ligands recognized by the proteome, (c) what are the relative frequencies of occurrence of sites for different small molecule ligands; (d) for how many known ligands, can sites be recognized in *Mtb*, (e) how many binding sites in *Mtb* are unique as compared to known binding pockets in PDB and (f) how does site-typing relate to sequence or structural fold based classification.

From the three site detection algorithms, 9029 pockets from 2809 proteins were chosen as consensus pockets. To this, 801 new binding pockets were added based on prior annotation in sequence databases. In addition, 4240 new sites from sequence motif searches in Prosite were also added. It must be noted that most sites added on from sequence based searches were also identified from structure based approaches but were not selected at that stage itself since they were not consensus predictions, meaning that at least one computational method failed to identify them. Full lists of *Mtb* protein structures and sites identified through different methods and information on other resources used are made available through a website - <http://proline.biochem.iisc.ernet.in/mtbpocketome/materials.php>. Overall, 13858 high confidence pockets were derived from the structural information currently available on all the proteins in *Mtb*. This includes 2877 sites, one each from the protein structural models of *Mtb*, that was recently studied in our laboratory, with a goal of obtaining structural annotation of the proteome[@b26]. Since the objective here is to define and characterize the pocketome, all consensus pocket predictions as well as all those with different experimental direct and indirect clues are included, which average to about 4 pockets per protein.

The pockets thus obtained are then analyzed for their ligand recognition properties by comparing them to known binding sites derived from PDB. Around 6906 pockets exhibited significant similarity in the entire pockets to some or the other known binding site in PDB ([Table S4](#s1){ref-type="supplementary-material"}), leading to deriving ligand associations for about 50% of the pocketome. In addition partial similarity is observed for 4695 more pockets as judged by PMIN score \> 0.5, together covering about 84% of the pocketome. Not surprisingly, these ligand associations capture most of the reported biochemical reactions in *Mtb*. [Figure 1A](#f1){ref-type="fig"} describes the coverage of the structural information available for proteins and the ligand annotations obtained for them in terms of KEGG pathways. [Figure 1B](#f1){ref-type="fig"} depicts the complete metabolic map currently known for *Mtb* from KEGG[@b53][@b54][@b55]. Highlighted in this map are proteins for which (a) structural models are available (edges colored in black) and (b) ligands whose associations with the proteins are characterized (red). The coverage of the reactome from this approach is seen to be high, indicating that most of the enzymes participating in cellular metabolism has been sufficiently captured in terms of enzyme structures that catalyze different reactions along with the information of binding site residues that could be involved in the molecular recognition of corresponding ligands. These can be interactively explored at <http://proline.biochem.iisc.ernet.in/mtbpocketome/pathways.php>.

Given that this analysis is carried out at a genome scale, it is possible to analyze the frequency of occurrence of different ligand binding sites. [Fig. 2](#f2){ref-type="fig"}, which illustrates this, serves qualitatively as a computational equivalent of a metabolome spectrum that can be obtained from a mass spectrometer for unit abundances of each binding site. The ligands are arranged according to their molecular weight on the x-axis. However, it must be noted that [Figure 2](#f2){ref-type="fig"} is derived using a novel methodology using structure-based function annotation concepts. The most frequently observed ligands through this approach turn out to be NAD followed by ADP, FAD and ATP. Ligands that can bind to the pocketome span a wide range of sizes, the smallest detected being 74 Da (tertiary-butyl alcohol) to about 1416 Da (bleomycin).

Binding site space of *Mtb* proteome is much higher than the sequence or the fold space
---------------------------------------------------------------------------------------

Next, to determine how many unique pocket types are present in *Mtb* proteome, we compared all detected binding pockets of *Mtb* to each other. We construct a binding site similarity network[@b56][@b57] with binding sites as nodes that are connected by edges only if the corresponding pair shared a similarity (Network-type 1, [Table S2](#s1){ref-type="supplementary-material"}). The sets of highly connected components were then identified from the network, through MCODE algorithm[@b38]. This exercise yielded 29 clusters from the connected components in the network ([Figure 3A](#f3){ref-type="fig"}), while the remaining proteins that shared no similarity with any other in the proteome were all singletons. Validation of our approach involving measure of binding site similarities, network construction and clustering, was carried out by applying an identical protocol to the MOAD dataset, a subset of protein-ligand complexes in PDB, from which expected clustering pattern was obtained as shown in [Figure 3B](#f3){ref-type="fig"} (see methodology section on validation). We refer to the 29 clusters obtained from the Mtb pocketome as 'sets' of proteins containing similar binding sites within each. By considering one representative of each set and adding onto the singletons, we find that the pocketome contains 6584 different types of pockets. We note that the exact number of unique site types is critically dependent on the site-similarity cut-off that is used. If the PMAX cut-off is lowered, the number of site-types become fewer due to partial similarities, but reduces sensitivity of the typing. If the PMAX cut-off is increased, the number of unique types increases significantly, leaning towards placing individual sites as singletons and thus of little use for understanding similarities. Since the purpose of site typing in this study is to identify group of sites that can bind to similar type of ligands, we use a cut-off of 0.6 PMAX, which we know from our earlier benchmarking analysis (PM), to be a cut-off that implies a high possibility of two sites recognizing a same ligand. In any case, all-pair similarities at different cut-offs are captured in [Figure 4](#f4){ref-type="fig"}. Since an all *vs* all comparison of binding sites resulted in about 96 million comparisons, its visualization and interpretation became challenging. To capture the essence of pocketome-wide comparisons, we have utilized the hexbin density plot ([Figure 4A](#f4){ref-type="fig"}) for visualization that illustrates the density distribution of PM global (PMAX) versus local similarity scores (PMIN) of all comparisons ([Figure 4A and 4B](#f4){ref-type="fig"}). We observe that of the 96 million unique pairs (of 192 million pair combinations), only a tiny fraction ([Figure 4D](#f4){ref-type="fig"}) - 0.4%, resemble each other closely in their entire sites and about 60% more exhibit part-similarity (PMIN \> 0.5) to each other. The fact that these pockets group into 6584 unique site-types indicate that the proteome is capable of atleast 6584 binding modes of small molecule recognition ([Supplementary Text 1](#s1){ref-type="supplementary-material"}).

Typing of binding sites immediately begs a question as to whether these could be detected by sequence and fold analyses alone. In order to see how many sequence types and similarly how many fold types constitute the *Mtb* proteome, all-pair sequence and fold comparisons were carried out. For each of the pocket pairs with significant similarity, values obtained from their corresponding sequence and fold level comparisons are plotted in [Figure 5](#f5){ref-type="fig"}. It can be seen from the figure that protein pairs exhibiting similar sites do not in many cases share either sequence or fold level similarities. Hence identifying similar ligand binding properties in pairs of proteins are not obvious from sequence and fold comparisons in many cases. The fact that *Mtb* proteome consists of around 1831 unique sequences in terms of Pfam domains[@b58], \~400 unique structural folds and about 1213 ligands, but 6584 binding site types, clearly indicate that the binding site space is much larger than the sequence or the fold space. The 6584 site types bind to the 1213 ligands and probably more yet to be characterized. Observation of these many different pocket types is suggestive of different modes of ligand recognition evolved to cater to specific functional requirements. Such fine-grained typing helps to understand specific ligands of the same class that the proteins can discriminate against. *Mtb* is known to be a highly redundant genome, with several paralogues for many proteins. Observations of subtle differences in binding sites are clearly indicative of the fine modulation of the ligand varieties required for specific molecular recognition.

[Figure 5](#f5){ref-type="fig"} also shows illustrative examples for binding site similarities observed at three different cases:(a) high sequence similarity and same-fold pairs representing the paralogue pairs in *Mtb* (b) low sequence similarity and same-fold pairs, and (c) low sequence similarity and different-fold pairs. The first case has been illustrated with an example of fibronectin proteins. There are three fibronectin binding proteins within *Mtb* (FbpA, FbpB and FbpC), all known to have mycolyl-transferase activity involving transfer of long-chain fatty acids to trehalose derivatives, resulting in high affinity of mycobacteria towards fibronectin. The structural superposition of two such proteins -- FbpA(Rv1886c) and FbpB(Rv3804c), along with their pocket alignment is illustrated in [Figure 5](#f5){ref-type="fig"}, showing high similarity in their pockets as might be expected and in a way serves as a positive control for the analysis. The second case involving pair of proteins sharing high structural and pocket similarity despite low sequence identity has been illustrated by an example of MbtB, a phenyloxazoline synthetase and Rv3087, a possible triacylglycerol synthase. Both these proteins are predicted to adopt CoA-dependent acyl transferase fold and further share similarity between correspondingly predicted pockets as depicted in [Figure 5](#f5){ref-type="fig"}. In the third case, high pocket similarity scores were observed for protein-pairs with no sequence or structural similarity. As an example illustrated here, a pocket in farnesyl pyrophosphate synthase (Rv1086) was found to share a significant similarity with another pocket in glycerol-3-phosphate dehydrogenase ([Figure 5](#f5){ref-type="fig"}). Both these genes are indirectly involved in lipid metabolism, and this similarity can possibly be exploited in structure-based drug discovery, as lipid metabolism is crucial for survival of *Mtb*.

Identifying polypharmacological target sets from Mtb binding site similarity network
------------------------------------------------------------------------------------

Analysis so far has identified binding pockets in Mtb proteome, estimated all-pair similarities among then and clustered sets of sites with significant similarities. The 29 binding site sets, thus identified, presents an opportunity to rationally select polypharmacological targets among them. It must be noted that the number of sets obtained can vary with the clustering algorithm used and PMAX cut-off defined to draw the edge due to inherent property of similarity network and the cluster resolution. Higher confidence is more important than the precise number of clusters. Hence we err on the side of caution and use a stringent threshold for deriving clusters. The proposed threshold was validated by carrying out similar analysis on pockets derived from MOAD dataset that resulted in obtaining sets containing highly similar chemical entities (average Tanimoto chemical similarity of \~0.8). Hence, we are confident about the similarity relationship that exists within the derived 29 sets through this workflow. [Figure 3A](#f3){ref-type="fig"} illustrates binding site similarity network and 29 distinct sets highlighted in different colors containing at least three sites in each set (superposition of binding sites within sets -- [Figure S2](#s1){ref-type="supplementary-material"}). Functional enrichment analysis carried out for each of these sets, indicate that proteins in these sets are well distributed across eight Tuberculist[@b59] functional classes and across 80 functional ontological terms, implying that these sites mediate a variety of functions ([Table 1](#t1){ref-type="table"}). The most abundant tuberculist category in the list is of intermediary metabolism and respiration, cell wall and cell processes followed by lipid metabolism.

A set of proteins that can bind to the same drug and have the properties desired in drug targets[@b60][@b61], would constitute first lists of polypharmacological targets. An ideal drug target needs to satisfy many criteria[@b60], many of which have already been studied previously in our laboratory. We therefore use the list of 451 drug targets identified as a high-confidence list derived from our previous study- targetTB[@b19]. This study incorporated a multi-level pipeline to identify proteins that have several qualities desired in ideal drug targets. The pipeline has several steps of filtering using systems level reactome and interactome analysis, sequence level comparative genomics with the host and a structure level assessment of druggability. The reactome and interactome analyses capture essentiality, while sequence and structural analyses capture specificity. The targetTB pipeline yielded prediction of 451 proteins as high confidence drug targets, some of which were already known in literature and many were new identifications. 20 of these targets in fact appear in 18 sets identified here. [Table 1](#t1){ref-type="table"} lists the sets and highlights those that are identified as promising drug targets in targetTB.

Identifying similarities to known drug binding sites
----------------------------------------------------

Our next goal was to screen the known drug binding sites (knowndrug-sites_DB) to identify site similarities with any of the shortlisted Mtb pockets. Any significant hit against the binding site sets would also be a good clue for being a possible lead with a polypharmacological profile. The database consisted of about 10658 binding sites for 1541 FDA-approved small molecule drugs, 150 FDA-approved biotech (protein/peptide) drugs, 86 nutraceuticals and 5082 experimental drugs. Interestingly, we observe at least one hit for most of the 29 sets. In all, 189 hits were obtained against 'known drug-site_DB'. [Figure 6](#f6){ref-type="fig"} illustrates the set of top ranked drug hits that can be associated to each set (Network-type 3, [Table S2](#s1){ref-type="supplementary-material"}). Some of the associated molecules from the Drugbank indeed correspond to the approved drugs subset, which are highlighted in [Figure 6](#f6){ref-type="fig"}.

Ranking the sites in the pocketome through polypharmacological potential index (PPI)
------------------------------------------------------------------------------------

In order to pick only those sites that are specifically druggable among the shortlisted proteins, we compute a polypharmacological index for each predicted binding site. Three aspects are considered in computing this index, which are, number of similar sites in the Mtb pocketome, implying polypharmacological possibility, number of drug clues obtained implying druggability and extent of specificity through number of druggable binding sites as compared to cofactor binding sites. The index thus (a) scores positively for the similarity of the sites to other sites in the pocketome and thus contribute to polypharmacological profile of the target (b) scores positively for those sets of sites that resemble any approved drug\'s known binding site and thus, indirectly implies druggability and (c) penalizes those sites that exhibit similarity to cofactor binding sites since that would increase chances of adverse polypharmacology[@b7][@b47]. Using this index, as described in [equation (1)](#m1){ref-type="disp-formula"}, we rank list the sets based on the polypharmacological indices of the individual sites contained in each set and observe that set12 and set13 are the top ranking sets. Set12 contains a binding site from a protein - Rv0687, a probable short-chain dehydrogenase/reductase, possibly involved in cellular metabolism and is found to be an essential gene through transposon site hybridization experiments[@b28]. Similarly, set13 also contains binding site of AccD3 (Rv0904c), a putative acetyl coenzyme A carboxylase that has been listed as essential for *Mtb* through various analyses[@b19]. Proteins containing sites with the highest PPI can be regarded to be most promising candidate sites for design of specific inhibitors, thus providing a list of possible polypharmacological drug targets. The top 20 high-scoring sites are derived from proteins that include - Pks2(Rv3825c), a polyketide synthase, PknD (Rv0931c), a transmembrane serine/threonine protein-kinase, which are already good targets as listed in targetTB 13 of these are also included in the TDR database[@b14] with a druggability score. Full list of targets containing the information on cofactor hits, drug hits, clustering-coefficient, PPI Score and normalized degree have been enlisted in [supplementary table (Table S5)](#s1){ref-type="supplementary-material"}. Targeting each set with a single drug can theoretically be envisaged to result in binding to and possibly modulating the function of all the members in that set simultaneously. Those that exhibited low PPI score are not considered as good polypharmacological targets by default. One reason for this could be that the binding sites in these resemble cofactor-binding sites and hence have a high frequency of occurrence. However, it must be noted that there are reports in literature which indicate successes for targeting cofactor-binding sites[@b62][@b63]. Careful design could achieve specific binding to the required sites.

Leads for polypharmacology of high confidence targets and clues for drug repurposing
------------------------------------------------------------------------------------

We systematically analyzed the subset of approved drug-sites from 'knowndrug-site_DB' that could serve as clues for lead design or drug repurposing, through construction of a bipartite network (Network-type 4, [Table S2](#s1){ref-type="supplementary-material"}) consisting of binding sites from 451 targetTB[@b19] drug targets and their similarities with binding sites of approved drugs. A bipartite network provides ready insights on two fronts, (a) rank list of drugs based on their clustering coefficient depicting the number of associations to different putative targets in *Mtb*, (b) rank list of proteins based on their clustering coefficient depicting the number of associations to approved drugs. While the first results in identification of polypharmacological sets, the second is useful for short-listing candidates for drug repurposing involving any drug target in *Mtb*. Since the same analysis can provide useful information to infer drug associations for all promising targets, in this exercise we do not restrict the analysis only to polypharmacological targets, instead we include all the targets identified from targetTB. [Supplementary Figure (Figure S4)](#s1){ref-type="supplementary-material"} illustrates the network, provides information about the list of targets for which a significant drug association is made and conversely a list of drugs for which a putative target in *Mtb* is identified. The clustering coefficient (CC~bp~) derived here for both protein and the drug is through projection of bipartite network onto corresponding single mode networks using *tnet* algorithm[@b64]. These promising drug associations are further verified by estimating the energetic feasibility of their binding at the given site through molecular docking (see Methodology section). Among the highly connected drugs are atazanavir, indinavir, lopinavir - antiretroviral drugs whose binding site in HIV virus bears similarity to proteins - PpsE(Rv2935), Rv2842c(conserved proteins), Rv2689c(conserved alanine and glycine rich protein), MurE(Rv2158c). These antiretroviral drugs were reported by Kinnings *et.al* in their TBDrugome[@b65] study as well. Further, there is indirect support from literature for the identification of ivermectin, another highly connected drug. Lim *et.al* have reported that it has antimycobacterial properties through the study of its effect on *Mtb* cultures of clinical strains and multidrug resistant strains[@b66]. Ivermectin is observed to have a high clustering coefficient in the network showing associations with SecY(Rv0732), MycP(Rv0291), DapD(Rv1201c) all identfiied as essential genes in *Mtb*. The whole set of associations obtained here can be regarded as ready shortlists for experimental testing. Targets with highest clustering coefficient in this network correspond to the most druggable targets. These include MurE protein, followed by LpdA protein. MurE is involved in cell wall formation and peptidoglycan biosynthesis, which is essential for mycobacterial survival while LpdA is a probable quinonereductase, already known to contribute towards virulence of *Mtb*. A full list of possible repurposable drugs and targets are listed in [Table 2](#t2){ref-type="table"} and [Table 3](#t3){ref-type="table"}. [Table 2](#t2){ref-type="table"} also lists down the essentiality criteria determined for each target obtained from our previous study[@b20] that incorporated analysis of microarray expression profiles, flux-balance analysis, protein-protein interaction network, phyletic retention and available literature on transposon site hybridization (TraSH) experiments.

Agreement with previously reported drug associations
----------------------------------------------------

One way of validating our approach is to analyze whether previously characterized associations from literature are identified in this approach. Isoniazid adduct, a front-line clinical drug for TB is well known to bind to its target InhA, an enoyl reductase. In addition, a crystallographic study also identifies its binding with DHFR[@b67]. It was indeed gratifying to observe that the binding sites of both InhA and DHFR were found to be similar with a PMAX of 0.52 (P-value = 8.4e-03) and PMIN score of 0.73 ([Figure 7](#f7){ref-type="fig"}).

A pull-down assay reported in literature by Argyrou *et.al*[@b68] independently identified 18 other proteins that bind to isoniazid adduct, which are perhaps secondary targets of this drug. We observe that 10 of the 18 proteins identified through this study (listed in [Table S6](#s1){ref-type="supplementary-material"}), including dihydrofolate reducatse, have binding sites similar to that in InhA, explaining the basis of such cross-reactivity.

A similar exercise was carried out for all the clinically used anti-tubercular drugs whose targets are well defined and where structural models are available of the complexes. The availability of these complexes enables us to extract out the binding site and compare against the pocketome. These drugs include cycloserine (DCS), para-amino salicylic acid (BHA), kanamycin (KAN), isoniazid (ISZ), rifampicin (RFP), rifabutin (RBT) and streptomycin (SRY). [Figure S3](#s1){ref-type="supplementary-material"} summarizes the results obtained for this analysis. Our analysis supports recently obtained experimental evidence on para-amino salicylic acid influencing the enzymes of the folate pathway[@b69][@b70][@b71] as many pockets belonging to the proteins in this pathway seem to have significant similarity to known binding site of PAS from p-hydroxybenzoate hydrolase ([Table S7](#s1){ref-type="supplementary-material"}).

An additional type of validation is to identify similarities in pairs of proteins previously reported in literature. A study by Kinnings *et al*., called TBDrugome[@b65], using structural models of about 1097 proteins, corresponding to about a third of our data, predicted pockets using a different algorithm and subsequent binding site comparisons also by a different method[@b65], has reported some drug associations with *Mtb* proteins. We have performed a systematic comparison of the drug associations obtained in this study with that reported in the study. Out of 1097 cases. 662 pockets were detected with the same ligand association (PMAX ≥ 0.4). It must be noted that in present work, the coverage of the proteome is much larger; binding pocket identification is much more rigorous involving multiple approaches and pocket comparison is carried out using a different algorithm that has been extensively validated against PDB. Given that detecting and comparing binding sites is a far from trivial exercise and is sensitive to the algorithm used, it is useful to have a comparison using two different approaches ([Supplementary Text 2](#s1){ref-type="supplementary-material"}). Our observation that many of the associations reported by TBDrugome[@b65] study forms a subset of our results serve to validate each other enhancing confidence for the whole set of drug associations.

Discussion
==========

Advances in genomics and related technologies are pushing the boundaries of the scale and resolution at which any organism or a given biological process is understood. This study, comprehensively studies a pocketome at the structural level, illustrating that the ligand binding space of the proteome can be probed algorithmically and utilized to obtain high resolution insights into several newly pursued aspects of drug discovery including polypharmacological target selection, combination targets and possible drug repurposing. Characterizing the pocketome at the structural level in *M.tuberculosis* appears to be among the first to study ligand-binding space comprehensively at the structural level in any organism. The novelty of the approach used in this study is to probe the entire set of small molecule binding sites in the organism through protein structures and the sub-structure comparisons in them. The workflow incorporates stringent steps of filtering and validation at each step. First, the structural models of the proteome used are already validated in our previous study through various stereochemical parameters and energetic considerations including secondary structure compatibility, informatics based statistical scoring of neighborhoods of each amino acid in each protein. Binding sites are picked based on a consensus prediction by three orthogonal binding site detection algorithms that capture residue conservation or evolutionary information, geometric parameters consistent with known binding sites and energetically favorable locations in the protein for ligand binding. Since individual methods have their own advantages as well as limitations, deploying a consensus approach is useful for overcoming individual limitations and hence enhances confidence. A large scale comparison with binding site residues known from sequence motifs or individual molecular biology experiments available in literature documented in databases, places the binding site predictions from this study in context of all available data in literature, making it possible to comprehend different evidences for ligand binding sites and hence ligand associations in a unified manner. Systematic comparisons to KEGG, PDB and Procognate ligand associations, are provided as a comprehensive resource through a web-accessible database. Such large-scale comparisons showing good agreement with different approaches automatically serves to validate currently used methodology themselves.

Binding site comparisons, which form the next step in the workflow, are carried out using home-grown algorithms previously reported and made available in literature. Tuning the algorithms for high-performance has rendered it feasible to carry out much of the analyses reported here, amounting to about 192 million comparisons, all at the structural level. Representing, analyzing and interpreting data from such large-scale comparisons presents the next challenge in the workflow, which has been addressed using network approaches. Network abstractions make a large amount of data computationally tractable using graph theoretical methods, an approach increasingly being used to analyze biological data[@b3][@b56][@b57][@b60]. Binding site networks constructed from all-pair comparisons include only those pairs that are sufficiently similar in their binding sites in the network. An algorithmic approach such as this allows for construction and probing of the network with different thresholds reflecting different stringencies, to cater to the specific question being asked of the network. Where drug associations are made for possible repurposing, a higher threshold is more meaningful so that associations made are of high confidence. This would mean that some associations that are still significant but below the threshold are missed out. Similarities at a lower threshold can still provide important clues for possible lead compounds, which can be obtained fairly easily with the network data obtained from this study. All data is therefore made available as a web accessible resource that is expected to be useful to the drug discovery community.

Network abstractions enable delineation of closely related communities or clusters reflecting sets of highly similar binding sites. Clustering methodology on a network such as this has been validated by performing a similar exercise on a dataset termed as MOAD, which contains well-curated high-resolution protein-ligand complexes from PDB. Obtaining separate clusters, each cluster containing chemically similar ligands indeed illustrates the capability of the approach to identify these clusters from a large data set.

Obtaining a definition of the pocketome in *Mtb* provides an unique opportunity to understand the range of binding sites present in the cell, set of possible ligands recognized by the cell, structural profile of the sites and the list of unique sites, leading to an understanding of the cellular functioning in terms of structural scaffolds that facilitate the underlying molecular recognition events. Knowledge of the binding sites at the structural level in each protein in the proteome provides a novel high-resolution approach for obtaining the predicted set of small molecules that participate in biochemical events in the cell or in other words a computational equivalent of a metabolome. Observation of recognizable binding sites in a number of conserved hypotheticals also provides significant clues to their possible functional roles, leading to new annotations. Ability to compare all-pair pockets at the structural level provides another new opportunity to identify number of unique binding site types represented by the genome. Observation that proteins similar even in sequence space and fold space exhibit significant differences in their site types point to the fact that the pocketome space is much larger than the sequence and fold space of the genome, suggesting that evolution of finer features of function, generation of ligand specificities and affinities has emerged through site variation alone.

Knowledge of the pocketome, similarities and differences among the individual sites in them has large implications for drug discovery. The importance of the right choice of the target protein, right at the start of the discovery pipeline, has been well recognized. Choice of target proteins have typically been largely guided by some prior knowledge of the protein or prior success with a related protein in a different condition and has not in many cases have had the advantage of a systematic exploration of the target space available for that condition. Selecting sets of proteins that share high similarity in their binding sites paves a well-lit path to identify polypharmacological targets. Abstraction of all-pair comparisons as networks facilitates identification of highly connected components or clusters in the networks, each cluster capturing one set of possible polypharmacological proteins. When this is integrated with knowledge from previous studies of drug target identification, it results in picking high-confidence targets that have additional criteria of being possible polypharmacological targets. Since databases such as Drugbank contain information about approved drugs and binding sites in their corresponding targets, it has become feasible to compare them with the pocketome of *Mtb* using the high-performance algorithms. The workflow in this study has yielded a ready shortlist of sets of promising drug targets with polypharmacological possibilities and at the same time has identified possible drug candidates either directly for repurposing or at the least as significant lead clues that can be used to design new drug molecules against the entire group of proteins in each set. In other words, it also identified compounds that have the potential to act as polypharmacological drugs. The PPI computed here captures this in a systematic manner at the same time ensuring that those sites such as cofactor binding sites seen often in the pocketome are filtered out.

In summary, this work defines the pocketome of *Mtb* by structural level characterization of the binding sites at a genome-scale, mapping ligands onto individual sites, which has lead to an understanding of the available pocketome space. The pocketome space is seen to be much larger then the sequence or the fold space, suggestive of the wide repertoire of specific functional roles achieved by the cell. On the other hand, the binding-site similarity network constructed has indicated the presence of about 29 sets together comprising about 121 proteins that share significant similarities within each set. These sets can now be exploited as possible polypharmacological target sets. A bipartite network derived by comparing known and approved drug binding sites to the pocketome has provided several significant drug associations for potential drug targets and thus important clues for possible drug repurposing. A list of approved drugs that could have new targets in *Mtb* is also obtained from the study. The approach used here is fairly generic and can be applied to other organisms as well, and can be incorporated in many drug discovery programmes.
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![An overview of the characterization of the enzymes in the Mtb pocketome, in terms of binding site analysis.\
(A) A stacked bar plot showing the coverage of protein structures and the confident ligand associations available with respect to the KEGG pathways. For each pathway the lower most bar in the stack corresponds to the number of genes or proteins in the pathway, the middle bar indicates the number of structural models available for the pathway and the top most stack indicates the number of proteins for which ligand annotations are made based on binding site structures. Each stack corresponds to one KEGG pathway in Mtb. (B) Metabolic map of central metabolism in Mtb, indicating extensive coverage of ligand annotation in the Mtb reactome from this study. The edges colored in black indicates the availability of protein structure catalyzing the reaction and the nodes colored in red represent the small ligand molecules taking part in the reaction for which the binding site has been mapped onto the respective protein structure.](srep06356-f1){#f1}

![An illustration of ligand associations for Mtb pocketome.\
Distribution of different ligand hits obtained for the predicted pockets in the proteome. The ligands are ordered by their molecular weights. The frequency on the Y-axis indicates the number of occurrences of the binding site of that ligand in the Mtb pocketome. This spectrum is qualitatively equivalent to the mass spectrum of the Mtb metabolome for unit protein abundances.](srep06356-f2){#f2}

![Binding Site Similarity networks.\
(A) The binding site similarity network obtained for Mtb Pocketome. Each node represents the predicted binding site and an edge between two nodes represents high similarity shared (PMAX ≥ 0.7) between them. The colors represent different clusters or sets of binding sites predicted by MCODE algorithm. (B) Binding site similarity network of pockets obtained from MOAD dataset, carried out as a validation exercise. The color of the nodes again depicts set of similar binding sites obtained from MCODE algorithm. Three such example clusters binding to ATP, heme and phosphoglycerate respectively are shown in enlarged version.](srep06356-f3){#f3}

![An overview of all-pair binding site similarities in Mtb Pocketome representing the results of 96 million comparisons (A) Hexbin plot depicts the distribution of all-pair similarity scores obtained using PocketMatch. The y-axis depicts the local or partial binding site similarity scores (PMIN) and the x-axis depicts the global-similarity scores (PMAX). The color of the hexbin represents the density of the scores obtained and is shown in the legend next to the plot. (B) Distribution of all-pair PMIN scores. (C) Distribution of all-pair PMAX scores. (D) Degree distribution of the sites in Mtb binding site similarity network, indirectly capturing number of similar sites.](srep06356-f4){#f4}

![An illustration of the structure-sequence-pocket space relationships in Mtb proteome.\
The 3D scatterplot depicts the distribution of high similarity pockets with respect to sequence and structural similarity scores obtained for the corresponding proteins. The color represents different categories of sequence-structure relationship and an example is highlighted from each of these categories with the depiction of proteins and pockets similarity.](srep06356-f5){#f5}

![Drug-hits for Polypharmacological targets.\
Each disconnected component represents a set of polypharmacological targets obtained from Mtb binding site similarity network. Two type of nodes are present in the network, the predicted binding sites are shown as spheres and the drugs sharing a binding site similarity are shown as triangles. The red colored circular nodes represent binding sites of high-confidence targets. Approved drugs are also highlighted in red.](srep06356-f6){#f6}

![A selected example of similar binding sites in different proteins predicted in this study matching with crystal structures available in literature (A) Structural superposition of dihydrofolate reductase (red cartoon) and InhA (blue cartoon, PDBID: 1ZID) protein based on the similarity of the binding sites (shown as sticks). The inset shows the similarity of the binding sites with the isoniazid adduct shown in ball and stick representation. (B) Crystal structure of dihydrofolate reductase with characterization of binding site for isoniazid adduct (PDBID: 2CIG).](srep06356-f7){#f7}

###### Binding Site Sets: A list of the proteins in the 29 binding sites sets, along with ontological terms associated with them. For each set, high scoring Drugbank hits are also listed. The proteins recognized as targets from targetTB study are highlighted in blue

  Binding Site Set                                       Accession Numbers                                                                                                                                                                                                                                                                 Ontology Terms                                                                                                                                                                                                                                                                                                                           DrugBank Hit
  ------------------ ----------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Set 1               Rv0015c;Rv0480cRv0973c;Rv0980cRv1004c;Rv1158cRv1230c;Rv1747Rv2407;Rv2589Rv2908c;Rv3629c   negative regulation of lipid biosynthetic process;protein phosphorylation;arylsulfatase activity;positive regulation of DNA binding;regulation of cell shape;plasma membrane;methylcrotonoyl-CoA carboxylase activity;negative regulation of catalytic activity;positive regulation of catalytic activity;protein serine/threonine kinase activity;protein kinase activity;protein autophosphorylation;protein binding;growth;cytosol;cell wall;extracellular region;                                                                Indolacetamide derivative (IOK); CO-5-Methoxybenzimidazolylcobamide (B1M);
  Set 2                                            Rv0620;Rv1276cRv1317c;Rv2524c                                                                                                                                                                                                                                  galactokinase activity;cell wall;cytosol;plasma membrane;growth;                                                                                                                                                                                                                                                 Progesterone (1CA);Benzenoid derivative (FHM);Colchicine (LOC);Quinolinone derivate (LGD);Benzonitrile (LGB);
  Set 3                                            Rv1272c;Rv2192cRv2276;Rv2690c                                                                                                                                                        anthranilate phosphoribosyltransferase activity;tryptophan biosynthetic process;carbon monoxide binding;heme binding;oxidoreductase activity;oxidation-reduction process;plasma membrane;growth;extracellular region;                                                                                                                                                                Bisadenosine-pentaphosphate (AP5);Biliverdine (BLA);Molybdenum (PCD);Pterine cytosine nucleotide (MCN);Succinyl coA (SCA);
  Set 4                              Rv0089;Rv0761cRv0849;Rv1761cRv1863c;Rv2194Rv2679;Rv2728c                                                                                                                                                                   heme binding;electron carrier activity;enoyl-CoA hydratase activity;electron transport;iron ion binding;plasma membrane;integral to plasma membrane;growth;cell wall;                                                                                                                                                                                                     Cyanocobalamin (CNC);FAD-isobutylketone (FAB);Pyrimidine ethanone adduct (TDT);HydroxyFAD (6FA);
  Set 5                                                Rv0527;Rv3319Rv3541c                                                                                                                                                                                                                         cytochrome complex assembly;succinate dehydrogenase activity;membrane;plasma membrane;growth;                                                                                                                                                                                                                              Phosphatidylethanolamine (PEE);Progesterone (1CA); Stearic acid (OLA);Colchicinoid derivative (CN2);Hexadecanal (PLM);
  Set 6                                            Rv2897c;Rv3521Rv3825c;Rv3871                                                                                                                                                                                             fatty acid biosynthetic process;cellular response to iron ion starvation;response to host immune response;plasma membrane;cell wall;cytosol;                                                                                                                                                                                       FAD-isobutylketone (FAB);Adenosine-pentaphosphate (UP5);Uridine-diPO4-acetylgulcosamine(UD1);Demethyl-dimethylamino FAD(RFL);4-oxo NAD-phosphate(ODP);
  Set 7                                         Rv0435c;Rv0941cRv1601;Rv3206cRv3791                                                                                                                                                                                           cysteine biosynthetic process;sulfotransferase activity;catalytic activity;active evasion of host immune response;plasma membrane;growth;                                                                                                                                                                                                  Cyclohexyl-beta-d-maltoside (MA4);Metylisoxazole (W35);Stearic acid (OLA); myristic acid (MYR); Phosphatidyl ethalnolamine (EPH);
  Set 8                                         Rv0538;Rv2393Rv2813;Rv3242cRv3923c                                                                                                                                                                                                                            ribonuclease P activity;sirohydrochlorin ferrochelatase activity;growth;                                                                                                                                                                                                       3-Acetylpyridine adenine dinucleotide (A3D);3-fluoro-5-morpholin-4-yl-N-benzamide (WBT);Nicotinamide Adenine Dinucleotide cyclohexanone (NDC);Lapatinib (FMM);Eicosapentanoic acid (EPA);
  Set 9                                   Rv0166;Rv0732Rv0978c;Rv1457cRv1795;Rv1941Rv2209                                                                                                                                                                                                                                                        NA                                                                                                                                                                                                                                                       3-Acetylpyridine adenine dinucleotide (A3D);Spironolactone (SNL);Aleglitazar (RO7); Nicotinamide Dinucleotide cyclohexanone (NDC);Quinolinone derivative (LGD);
  Set 10                                           Rv0274;Rv1141cRv2842c;Rv3011c                                                                                                                                                                                                                                            enoyl-CoA hydratase activity;plasma membrane;                                                                                                                                                                                                                                3-Acetylpridine adenine dinculeotide (A3D);Analogue of Indinavir (XN2);Pyrimidine ethanone adduct (TDT);Demethyl-dimethylamino FAD (RFL);5,6-dihydroxy-NADP (NZQ);
  Set 11                                           Rv0194;Rv0343Rv1675c;Rv1838c                                                                                                                                                                                        efflux transmembrane transporter activity;regulation of transcriptionDNA-dependent;regulation of growth;DNA binding;plasma membrane;cell wall;cytosol;                                                                                                                                                                            Cyclohexyl-beta-d-maltoside (MA4);Oleic acid (OLA);Isoquinolinone derivative (IZA);Isoindoloindolone derivative (CZA); Ethoxypyridine acetamide derivative (877);
  Set 12                                           Rv0687;Rv2158cRv2629;Rv3072c                                                                                                                                                                                                                                             response to hypoxia;cytosol;plasma membrane;                                                                                                                                                                                                                                          FAD-isobutylketone (FAB); Analogue of Indinavir (XN2);Tipranavir (TPV);Pyrimidine ethanone adduct (TDT); Carmbamic acid tert-butyl ester (Q50);
  Set 13                                           Rv0904c;Rv1358Rv2988c;Rv3700c                                                                                                                                                                                                                                 mycolic acid biosynthetic process;protein binding;plasma membrane;                                                                                                                                                                                                                                    Retronavir (RIT);Lopinavir (AB1); Analogue of Indinavir (XN2);3-fluoro-5-morpholin-4-yl-N-benzamide (WBT); Benzamide derivative (P40);
  Set 14                                     Rv0148;Rv0291Rv0557;Rv1863cRv1918c;Rv3910                                                                                                                                                                                                                        integral to plasma membrane;growth;plasma membrane;extracellular region;                                                                                                                                                                                                                 Oleic acid (OLA); Adenosine-5-Diphosphoribose (APR); Colchicinoid derivative (CN2);Dimethyl phenyln propanamide derivative (G1L); Pyridine acetamide derivative (877);
  Set 15                                               Rv1086;Rv2383cRv2982c                                                      Z-farnesyl diphosphate synthase activity;di-transpoly-cis-decaprenylcistransferase activity;glycerol-3-phosphate dehydrogenase \[NAD(P)+\] activity;phosphopantetheine binding;polyprenol biosynthetic process;acyl carrier activity;siderophore biosynthetic process;cellular response to iron ion starvation;manganese ion binding;plasma membrane;magnesium ion binding;response to host immune response;pathogenesis;cytosol;                                                      Phosphatidyl ethanolamine (PEE); Colchicinoid derivative (CN2);Oleic acid (OLA); Progesterone (1CA); Propanamide derivative (FHM);
  Set 16                                               Rv1125;Rv1248cRv3729                                                                                                                                 2-oxoglutarate decarboxylase activity;oxoglutarate dehydrogenase (succinyl-transferring) activity;pyruvate dehydrogenase complex;tricarboxylic acid cycle;electron carrier activity;oxidation-reduction process;plasma membrane;magnesium ion binding;protein binding;growth;                                                                                                                      Petrin cytosine dinucleotide (MCN);Molybdenum cofactor (PCD); FAD-isobutylketone (FAB); Co-cyanocobalamin (CNC); Bis-adenosine 5-pentaphosphate (AP5);
  Set 17                                              Rv0070c;Rv2381cRv3029c                                                                                                                                                                                                           glycine hydroxymethyltransferase activity;electron carrier activity;electron transport;plasma membrane;cytosol;growth;                                                                                                                                                                                       Cyclohexyl-beta-d-maltoside (MA4); Isoindoloindolone derivative (CZA); Isoquinolinone derivative (IZA); Carbothiomide derivative (DKI); Pyridine acetamide derivative (877);
  Set 18                                               Rv1400c;Rv1683Rv2029c                                                                                                                                                                                                                         poly-hydroxybutyrate biosynthetic process;acyltransferase activity;growth;plasma membrane;                                                                                                                                                                                                               Cyclohexyl-beta-d-maltoside (MA4); Pyridine carboxamide derivative (ZZY); Thiazolone derivative (ZMG); Purinamine derivative (ZIP); Stearic acid (STE);
  Set 19                                               Rv0125;Rv0304cRv2683                                                                                                                                                                                                                                                             extracellular region;                                                                                                                                                                                                                                 Cyclohexyl-beta-d-maltoside (MA4); Isoindoloindolone derivative (CZA); Hydroxy ocatadeca-didenoic acid (243); Dihydropyrimidine amine derivative (YF4); Hydroxy-3-methoxybenzoate (VNL);
  Set 20                                               Rv0651;Rv3448Rv3573c                                                                                                                                                                                                                                           ribosome biogenesis;intracellular;plasma membrane;growth;                                                                                                                                                                                                         Oleci acid (OLA); Ethylpyrimidine diamine derivative (N22); Cyclohexyl-beta-d-maltoside (MA4); Methylpyridazine piperidine propyloxyphenylacetate (J78); Phosphotidyl ethanolamine derivative (EPH);
  Set 21                                               Rv0512;Rv1066Rv2075c                                                                                                                                                                                                                                                                      NA                                                                                                                                                                                                                                                                                            Imatinib (STI); Lopinavir (AB1); Tipranavir (TPV); Ritonavir (RIT); Raloxifine (RAL);
  Set 22                                               Rv1666c;Rv2383cRv3087                                                                                                                                                                          phosphopantetheine binding;acyl carrier activity;siderophore biosynthetic process;cellular response to iron ion starvation;response to host immune response;pathogenesis;plasma membrane;                                                                                                                                                                       Co-cyanocobalamin (CNC); Pyrimidine ethanone adduct (TDT); Phosphatidylethanolamine (PEE); PentadecylcoA (NHM); TetradecanoylcoA (MYA);
  Set 23                                               Rv0702;Rv3224Rv3702c                                                                                                                                                                                                                                                 response to iron ion;cytosol;plasma membrane;                                                                                                                                                                                                                                   Biliveridine (BLA); Phenyl acetic acid derivative (965); FAD-isobutylketone (FAB); Analogue of Indinavir (XN2);3-fluoro-5-morpholin-4-yl-N-benzamide (WBT);
  Set 24                                               Rv0767c;Rv1181Rv3158                                                                                                                                                                                                             NADH dehydrogenase (ubiquinone) activity;integral to plasma membrane;extracellular region;cell wall;plasma membrane;                                                                                                                                                                                                               Biliverdine (BLA); Succinyl CoA (SCA); 3-Acetylpyridine adenine dinucleotide (A3D);4-oxo NADP (ODP); 5,6-dihydroxy NADP (NZQ);
  Set 25                                               Rv0843;Rv1877Rv3757c                                                                                                                                                                                                               binding;glycine betaine transport;response to host;transporter activity;transport;membrane;extracellular region;                                                                                                                                                                                            Cyclohexyl-beta-d-maltoside (MA4); CZA (Isoindoloindolone derivative); Isoindoloindolone derivative (IZA); Ethoxypyridine acetamide derivative (877); Crizotinib (VGH);
  Set 26                                               Rv1181;Rv1979cRv3825c                                                                                                                                                                                                fatty acid biosynthetic process;cellular response to iron ion starvation;cell wall;response to host immune response;plasma membrane;cytosol;                                                                                                                                                                                                    Molybdenum (PCD); Bilivridine (BLA); Pterin cytosine dinucleotide (MCN); Co-cyanocobalamin (CNC); FAD-isobutylketone (FAB);
  Set 27                                               Rv1361c;Rv1800Rv3144c                                                                                                                                                                                                                                                      response to host immune response;                                                                                                                                                                                                                                                          Imatinib (STI); Biliverdine (BLA); Digalactosyl diacy glycerol (DGD); Eicosapentaenoic acid (EPA); Arachidonic acid (ACD);
  Set 28                                               Rv1438;Rv3021cRv3585                                                                                                                                                                                 DNA helicase activity;DNA replication;triose-phosphate isomerase activity;plasma membrane;ATP binding;protein homodimerization activity;cytosol;growth;extracellular region;                                                                                                                                                                    Cyclohexyl-beta-d-maltoside (MA4);Crizotinib (VGH); Pyrazoloquinolinone (73Q); Pyridine carboxamide derivative (ZZY); Diphenyl indole carboxylic acid (VX3);
  Set 29                                               Rv1832;Rv2677cRv3578                                                                                                                                                                                                    glycine dehydrogenase (decarboxylating) activity;oxygen-dependent protoporphyrinogen oxidase activity;cell wall;plasma membrane;growth;                                                                                                                                                                                                      Biliverdine (BLA); Molybdenum (PCD); Pterine cytosine nucleotide (MCN); Succinyl CoA (SCA); Phosphatidylethanolamine (PEE);
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###### Prioritized Drug Targets: Ranking putative drug targets from targetTB H-list, based on the number of connections to approved drugs from the databases used in this study. The description of each protein along with its clustering coefficient (CC) value in the bipartite network has been listed. The essentiality inference of the targets obtained from Ghosh *et.al* 2013, has also been indicated, these include (A) Microarray analysis, (B) Flux balance analysis, (C) Protein-protein interaction analysis, (D) Phyletic retention analysis and (E) Transposon hybridization experiments

  Protein    Gene Name   CC~bp~   Essentiality Inference                                                                       Protein Description
  --------- ----------- -------- ------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------
  Rv2158c     *murE*      0.77        A; B; C; D; E                                               ProbableUDP-N-acetylmuramoylalanyl-D-glutamate-2,6-diaminopimelate ligase MurE
  Rv2842c     Rv2842c     0.72              A                                                                             Conserved hypothetical protein
  Rv3303c     *lpdA*      0.71           A; D; E                                                                          NAD(P)H quinone reductase LpdA
  Rv2335      *cysE*      0.66          A; B; C; E                                                                 Probable serine acetyltransferase CysE (sat)
  Rv2398c     *cysW*      0.63           A; D; E                                                    Probable sulfate-transport integral membrane protein ABC transporter CysW
  Rv2689c     Rv2689c     0.61             A; D                                                               Conserved alanine and valine and glycine rich protein
  Rv3139     *fadE24*     0.59           A; D; E                                                                      Probable acyl-CoA dehydrogenase FadE24
  Rv2935      *ppsE*      0.58             A; B                                                             Phenolpthiocerol synthesis type-I polyketide synthase PpsE
  Rv2026c     Rv2026c     0.58           A; D; E                                                                          Conserved hypothetical protein
  Rv0914c     Rv0914c     0.55             A; D                                                              Possible lipid carrier protein or keto acyl-CoA thiolase
  Rv3343c     *ppe54*     0.52             A; E                                                                              PPE family protein PPE54
  Rv2388c     *hemN*      0.52          A; B; C; D                                  Probable oxygen-independent coproporphyrinogen III oxidase HemN (coproporphyrinogenase) (coprogen oxidase)
  Rv0542c     *menE*      0.48          A; C; D; E                                   Possible O-succinylbenzoic acid\--CoA ligase MenE (OSB-CoA synthetase) (O-succinylbenzoate-CoA synthase)
  Rv3245c     *mtrB*      0.48           A; D; E                                                             Two component sensory transduction histidine kinase MtrB
  Rv2900c     *fdhF*      0.46              A              Possible formate dehydrogenase H FdhF (formate-hydrogen-lyase-linked, selenocysteine-containing polypeptide) (formate dehydrogenase-H alpha subunit) (FDH-H)
  Rv0220      *lipC*      0.45             A; D                                                                               Probable esterase LipC
  Rv1220c     Rv1220c     0.45              A                                                                               Probable methyltransferase
  Rv3801c    *fadD32*     0.43          A; B; D; E                       Fatty-acid-AMP ligase FadD32 (fatty-acid-AMP synthetase) (fatty-acid-AMP synthase). Also shown to have acyl-ACP ligase activity.
  Rv1613      *trpA*      0.43           A; B; E                                                                 Probable tryptophan synthase, alpha subunit TrpA
  Rv2573      Rv2573      0.42          A; B; C; E                                                                        Conserved hypothetical protein
  Rv2678c     *hemE*      0.42          A; B; C; E                                       Probable uroporphyrinogen decarboxylase HemE (uroporphyrinogen III decarboxylase) (URO-D) (UPD)

###### Approved Drugs with potential for repurposing in tuberculosis. Identified hits from the list of Approved drugs, listed in the order of clustering coefficient (CC) in the bipartite network. Inferred Mtb targets for the corresponding drug based upon the associations in the bipartite network have also been listed

  Drug Name                       CC~bp~                                                                                                                                                                               Inferred targets in Mtb                                                                                                                                                                                                                                                                                                                                                      Known pharmacological action
  ------------------------------ -------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Atazanavir (DB01072;DR7)          1                                                                                                                                                                              Rv2026c; Rv2335; Rv1220; Rv2935                                                                                                                                                                           Used in combination with other antiretroviral agents for the treatment of HIV-1 infection, as well as postexposure prophylaxis of HIV infection in individuals who have had occupational or nonoccupational exposure to potentially infectious body fluids of a person known to be infected with HIV when that exposure represents a substantial risk for HIV transmission.
  Indinavir (DB00224;MK1)          0.95                                                                                                                                                              Rv2158c; Rv2026; Rv2335; Rv2842c; Rv1220c; Rv2689c; Rv2935                                                                                                                                                                                                                                                                                                                Indinavir is an antiretroviral drug for the treatment of HIV infection.
  Lopinavir (DB01601;AB1)          0.86                                                                                                                                                                  Rv0542c; Rv1663; Rv2678c; Rv2842c; Rv2689c; Rv2935                                                                                                                                                                                                                                                                                                         Indicated in combination with other antiretroviral agents for the treatment of HIV-infection
  Saquinavir (DB01232;ROC)         0.81                                                                                                              Rv2158c; Rv0904c; Rv2026c; Rv3303c; Rv2510c; Rv0627; Rv1663; Rv2335; Rv2946c; Rv2996c; Rv2678c; Rv2842c; Rv0237c; Rv1220c′ Rv2689c; Rv1505c; Rv2935; Rv2931                                                                                                                                                                                                                                            For the treatment of HIV-1 with advanced immunodeficiency together with antiretroviral nucleoside analogues.
  Nelfinavir (DB00220;1UN)         0.77                                                                                                                                                 Rv0237; Rv1663; Rv1843c; Rv2026c; Rv2678c; Rv2689c; Rv2842c; Rv2935; Rv3303c; Rv3882c                                                                                                                                                                                                                                                                                    Used in combination with other antiviral drugs in the treatment of HIV in both adults and children
  Nilotinib (DB04868;NIL)          0.7                                                                                                                                                 Rv0237; Rv1663; Rv1843c; Rv2026c; Rv2678c; Rv2689c; Rv2842c; Rv2935; Rv3303c; Rv3882c;                                                                                                                                                                                                                                                                                        For the potential treatment of various leukemias, including chronic myeloid leukemia (CML)
  Tipranavir (DB00932;TPV)         0.69                                                                                                                              Rv0555; Rv0904c; Rv1127c; Rv1550; Rv1663; Rv2026c; Rv2153c; Rv2388c; Rv2678c; Rv2689c; Rv2726c; Rv3825c; Rv3883c; Rv3886c;                                                                                                                                                                                                          For combination antiretroviral treatment of HIV-1 infected adult patients with evidence of viral replication, who are highly treatment-experienced or have HIV-1 strains resistant to multiple protease inhibitors
  Ritonavir (DB00503;RIT)          0.68                                                                                                    Rv0511; Rv0627; Rv0904c; Rv1092c; Rv1220c; Rv1237; Rv1663; Rv1843c; Rv2026c.; Rv2335; Rv2388c; Rv2678c; Rv2689c; Rv2842c; Rv2935; Rv3303c; Rv3509c; Rv3582c; Rv3825c; Rv3886c;                                                                                                                                                                                                                                           Indicated in combination with other antiretroviral agents for the treatment of HIV-infection.
  Rosiglitazone (DB00412;BRL)      0.66                                                                                                                                                                          Rv0755c; Rv1753c; Rv1886c; Rv3804c;                                                                                                                                                                                                                                                                                                                                       For the treatment of Type II diabetes mellitus
  Amprenavir (DB00701;478)         0.64                                                                       Rv0085; Rv0237; Rv0478; Rv0635; Rv1127c; Rv1237; Rv1505c; Rv1542c; Rv1655; Rv1663.2; Rv1843c; Rv1850; Rv2153c; Rv2524c; Rv2524c; Rv2613c; Rv2689c; Rv2931; Rv2938; Rv2939; Rv3135; Rv3245c; Rv3804c; Rv3882c; Rv3883c; Rv3886c; Rv3887c;                                                                                                                                                                                                                  For the treatment of HIV-1 infection in combination with other antiretroviral agents.
  Gefitinib (DB00317;IRE)          0.61                                                                                                                                                      Rv0085; Rv0291; Rv1287; Rv1836c; Rv2156c; Rv2296; Rv2869c; Rv2889c; Rv3737;                                                                                                                                                                                                                                                     For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.
  Tamoxifen (DB00675;CTX)          0.61                                                                                                                                     Rv0228; Rv0237; Rv0290; Rv0527; Rv0545c; Rv1650; Rv1836c; Rv2281; Rv2439c; Rv2678c; Rv2986c; Rv3722c; Rv3737;                                                                                                                                                                                                                                                                                                        For the treatment of breast cancer.
  Dasatinib (DB01254;1N1)          0.61                                                                                                                                                                  Rv2069; Rv2202c; Rv2231c; Rv2727c; Rv3372; Rv3886c;                                                                                                                                                                                                                                                                     For the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy.
  Darunavir (DB01264;017)          0.6                                                                                                                       Rv0542c; Rv1237; Rv1409; Rv1663; Rv2026c; Rv2153c; Rv2158c; Rv2613c; Rv2678c; Rv2689c; Rv2842c; Rv2897c; Rv2935; Rv3255c; Rv3825c; Rv3886c;                                                                                                                                                       Darunavir, co-administered with ritonavir, and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (HIV) infection in antiretroviral treatment-experienced adult patients, such as those with HIV-1 strains resistant to more than one protease inhibitor.
  Adenosine (DB00640;ADN)          0.59                                                                                                          Rv0032; Rv0291; Rv0479c; Rv0509; Rv0545c; Rv1201c; Rv1650; Rv1836c; Rv1843c; Rv2296; Rv2482c; Rv2869c; Rv3037c; Rv3255c; Rv3579c; Rv3737; Rv3740c; Rv3825c; Rv3909;                                                                                                                                                               Used as an initial treatment for the termination of paroxysmal supraventricular tachycardia (PVST), including that associated with accessory bypass tracts, and is a drug of choice for terminating stable, narrow-complex supraventricular tachycardias (SVT).
  Vinblastine (DB00570;VLB)        0.59                                                                                                                                                                          Rv0914c; Rv2196; Rv2398c; Rv3882c;                                                                                                                                                                                                                                                                        For treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin\'s and non-Hodgkin\'s lymphomas, mycosis fungoides, histiocytosis, and Kaposi\'s sarcoma.
  Spironolactone (DB00421;SNL)     0.59                                                                                                                                                Rv0732; Rv0914c; Rv1181.4; Rv1795; Rv2113; Rv2196; Rv2398c; Rv3801c; Rv3825c; Rv3882c;                                                                                                                                                                                                                                                                                            Used primarily to treat low-renin hypertension, hypokalemia, and Conn\'s syndrome.
  Colchicin (DB01394;LOC)          0.57                                                                                                                 Rv0032; Rv0474; Rv0570; Rv0732; Rv1181; Rv1296; Rv1300; Rv1380; Rv1655; Rv2113; Rv2156c; Rv2178c; Rv2281; Rv2524c; Rv3037c; Rv3712; Rv3882c; Rv3886c;                                                                                                                                                                                                                                                                   For treatment and relief of pain in attacks of acute gouty arthritis.
  Podofilox (DB01179;POD)          0.56                                                                                                    Rv0474; Rv0570; Rv0732; Rv0904c; Rv1181; Rv1296; Rv1300; Rv1550; Rv1650; Rv1795; Rv2113; Rv2156c; Rv2178c; Rv2259; Rv2281; Rv3015c; Rv3037c; Rv3712; Rv3790; Rv3882c; Rv3886c;                                                                                                                                                                                                                                                          For treatment of external genital warts (Condyloma acuminatum).
  Lapatinib (DB01259;FMM)          0.56    Rv0237; Rv0511; Rv0527; Rv0545c; Rv0554; Rv0555; Rv0570; Rv0724; Rv0732; Rv0904c; Rv1127c; Rv1181; Rv1220c; Rv1485; Rv1505c; Rv1530; Rv1650; Rv1663; Rv1843c; Rv1872c; Rv1905c; Rv2165c; Rv2231c; Rv2439c; Rv2524c; Rv2610c; Rv2613c; Rv2623; Rv2678c; Rv2897c; Rv2902c; Rv2941; Rv3255c; Rv3405c; Rv3582c; Rv3585; Rv3635; Rv3737; Rv3825c; Rv3871; Rv3882c; Rv3886c; Rv3887c;                                            Indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal receptor type 2 (HER2) protein and who have received prior therapy including an anthracycline, a taxane, and trastuzuma.
  Imatinib (DB00619;STI)           0.55                                                                                         Rv0120c; Rv0627; Rv0843; Rv0904c; Rv1078; Rv1127c; Rv1237; Rv1287; Rv1293; Rv1409; Rv1459c; Rv1492; Rv1542c; Rv1843c; Rv2153c; Rv2170; Rv2231c; Rv2610c; Rv2613c; Rv2623; Rv2869c; Rv2996c; Rv3132c;                                                                                                                                                                                                           For the treatment Philadelphia chromosome positive chronic myeloid leukemia (CML) and malignant gastrointestinal stromal tumors (GIST)
  Bexarotene (DB00307;9RA)         0.55                                                                                                                                                                      Rv0755c; Rv1237; Rv1753c; Rv1886c; Rv3804c;                                                                                                                                                                                                                                                                           Used orally for the treatment of skin manifestations of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy.
  Raloxifene (DB00481;RAL)         0.54                                                                Rv0237; Rv0627; Rv0904c; Rv1204c; Rv1237; Rv1277; Rv1459c; Rv1505c; Rv1650; Rv1653; Rv1663; Rv2026c; Rv2124c; Rv2388c; Rv2439c; Rv2524c; Rv2573; Rv2613c; Rv2678c; Rv2935; Rv2938; Rv2946c; Rv3097c; Rv3132c; Rv3405c; Rv3585; Rv3800c; Rv3804c;Rv3825c                                                                                                                                                                           For the prevention and treatment of osteoporosis in post-menopausal women, as well as prevention and treatment of corticosteroid-induced bone loss.
  Prednisone (DB00635;PDN)         0.53                                                                                                                                                             Rv0256c; Rv1237; Rv1613; Rv1886c; Rv2900c; Rv3245c; Rv3343c;                                                                                                                                                                                                For the treatment of drug-induced allergic reactions, perennial or seasonal allergic rhinitis, serum sickness, giant cell arteritis acute rheumatic or nonrheumatic carditis, systemic dermatomyositis, systemic lupus erythematosus, atopic dermatitis, contact dermatitis, exfoliative dermatitis.
  Erythromycin (DB00199;ERY)       0.53                                                                                                                                                          Rv1181; Rv1257c; Rv1589; Rv2243; Rv3712; Rv3793; Rv3801c; Rv3886c;                                                                                                                                                                                              For use in the treatment of infections caused by susceptible strains of microorganisms in the following diseases: respiratory tract infections (upper and lower) of mild to moderate degree, pertussis (whooping cough), as adjunct to antitoxin in infections due to Corynebacterium diphtheriae.
  Progesterone (DB00396;STR)       0.53                                                                                                                                    Rv0220; Rv0724; Rv1237; Rv1613; Rv1753c; Rv1886c; Rv2900c; Rv2938; Rv3245c; Rv3343c; Rv3801c; Rv3804c; Rv3825c;                                                                                                                                                                                                                                         For progesterone supplementation or replacement as part of an Assisted Reproductive Technology (ART) treatment for infertile women with progesterone deficiency
  Ivermectin (DB00602;IVM)         0.53                                                                                                                             Rv0032; Rv0256c; Rv0291; Rv0527; Rv0545c; Rv0585c; Rv0732; Rv1201c; Rv1385; Rv1613; Rv1714; Rv2113; Rv2938; Rv3255c; Rv3825c;                                                                                                                                                             For the treatment of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite Strongyloides stercoralis. Also for the treatment of onchocerciasis (river blindness) due to the nematode parasite Onchocerca volvulus. Can be used to treat scabies caused by *Sarcoptes scabiei*.
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